GL Pharm Tech Corp. (KOSDAQ:204840)

Market Cap	92.27B
Revenue (ttm)	34.30B
Net Income (ttm)	307.33M
Shares Out	77.22M
EPS (ttm)	4.24
PE Ratio	281.88
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	286,206
Average Volume	216,460
Open	1,180.00
Previous Close	1,188.00
Day's Range	1,155.00 - 1,243.00
52-Week Range	900.00 - 1,844.00
Beta	0.95
RSI	47.14
Earnings Date	Mar 18, 2026

About GL Pharm Tech

GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disease, transplantation, and other areas. In addition, the company engages in developing new molecule entity pipeline products for dry eye disease. Further...

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 33
• Stock Exchange: KOSDAQ
• Ticker Symbol: 204840

Financial Performance

In 2024, GL Pharm Tech's revenue was 26.05 billion, an increase of 0.06% compared to the previous year's 26.03 billion. Losses were -2.34 billion, -37.64% less than in 2023.